<h2 class="depth2_title02">Novel Protein Drug for Stroke</h2> <h3 class="depth3_title">개발자</h3> <p class="depth3_txt">허지회 교수(MD, Ph.D, Dept. Neurology)</p> <h3 class="depth3_title02">기술개요</h3> <p class="depth3_txt">Intravenous (IV) administration of recombinant tissue plasminogen activator (rt-PA) is an effective treatment for ischemic stroke if administered within 4.5 hours of symptom onset. However, more than two-thirds of patients fail to achieve successful recanalization after IV rt-PA treatment. rt-PA also has neurotoxic effects. To improve thrombolytic potency and reduce the potential adverse effects of rt-PA, several new thrombolytic agents have been developed. However, up to now, there has not been prososed clinically satisfactory drugs for ischemic stroke. Accordingly, there remains a long-felt need in new drugs for ischemic stroke with enhanced thromobolysis activity and safety that have other mode of action than fibrinolysis.</p> <h3 class="depth3_title02">기술설명</h3> <div class="depth3_txt float_wrap severance"> <span class="float_left">Fig) Dose-dependent thrombolytic effects of rt-PA in FeCl3-induced carotid artery thrombosis mouse models. The core technology is to provide a new protein drug candidate for ischemic stroke that has enhanced thromobolysis activity and safety by other mode of action than fibrinolysis. The protein drug candidate developed and validated has been elucidated to possess higher thromobolytic potency than recombinant tissue plasminogen activator (rt-PA) and good safety by targeting integrins (e.g., GP IIb/IIIa) on platelets.</span> <span class="float_right"><img alt="The time-flow curve in each animal 그래프" src="/resources/images/rdh/content/severanceHospital/severanceHospital_etc05_08.gif"></span> </div> <h3 class="depth3_title02">기술특징</h3> <ul class="depth3_txt dot_lstyle"> <li>The protein drug candidate exhibits stroke treatment by dual functions including thrombolysis and suppression of neuroinflammation. Such dual treatment approaches by a single API (active pharmaceutical ingredient) are very unique and effective in stroke treatment.</li> <li>The stroke therapy of the protein drug candidate is accomplished by the mode of action, thrombolysis through binding to integrins on platelets (e.g., GP IIb/IIIa) and suppression of neuroinflammation through binding to integrins on neutrophils (e.g., αMβ2andαLβ2).</li> <li>The protein drug candidate has been validated to exhibit good safety in mouse model. In particular, bleed complications were not observed in the treatment group</li> <li>The protein drug candidate can be produced using our Pichia exprssion system with good mass productivity for clinical tests and commercialization.</li> </ul> <h3 class="depth3_title02">활용분야</h3> <div class="depth3_txt float_wrap severance"> <div class="float_left"> <p>Acute Ischemic Stroke: Global Market Value to Grow Significantly by 2017</p> <ul class="dot_lstyle"> <li>The acute ischemic stroke (AIS) therapeutics market in the six major countries - the US, France, Germany, Italy, Spain and UK - is forecast to jump from $531m in 2012 to $1.2 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 17.3%.</li> <li>The US market will continue to generate the majority of sales, more than doubling its revenue from $376.4m in 2012 to $945.4m by 2017, at a CAGR of 20.2%. This is due to the US </li> </ul> </div> <div class="float_right"><img alt="그래프" src="/resources/images/rdh/content/severanceHospital/severanceHospital_etc05_09.gif"></div> </div> <h3 class="depth3_title02">연락처</h3> <ul class="depth3_txt dot_lstyle"> <li>담당자 : 장규진</li> <li>소속 : 연세의료원 산학협력단</li> <li>이메일 : kjjang@yuhs.ac.kr</li> <li>연락처 : 02-2228-0295</li> </ul>
소스입니다. Ctrl+C를 눌러 클립보드로 복사하세요

닫기